Key result
Terminalia muelleri attenuates iron accumulation and oxidative cardiac damage in doxorubicin-induced cardiotoxicity.
Why the study?
Cardiovascular dysfunction frequently complicates antineoplastic treatment, and limited cardiac cell regeneration renders myocytes particularly susceptible to long-term adverse effects of anthracyclines.
Does Terminalia muelleri attenuate oxidative cardiac damage in rats with doxorubicin-induced cardiotoxicity?
Does Terminalia muelleri attenuate oxidative cardiac damage in rats with doxorubicin-induced cardiotoxicity?
In a preclinical rat model, Terminalia muelleri is investigated for its potential to attenuate doxorubicin-induced cardiotoxicity.
Answers are grounded in this paper and cite their sources.
Supports hypothesis generation for Terminalia muelleri in doxorubicin cardiotoxicity; does not yet inform clinical practice.
C ardiovascular system dysfunction is one of the most frequent consequences of exposure to antineoplastic treatment, whereas cardiovascular diseases and cancers are the leading causes of morbidity and mortality in the world (Sung et al., 2021).The less regeneration ability of cardi-ac cells renders cardiac myocytes to be more prone to the long-term adverse effects of chemotherapy agents such as anthracycline (Hardaway, 2019).Cardiotoxicity is the toxicity that affects the heart.This definition is attributed to the effect of chemotherapy on the entire cardiovascular system that occurs through di-research
No takes yet. Share an insight, caveat, or question.
Eltablawy et al. (2022) studied Doxorubicin-induced cardiotoxicity. Terminalia muelleri was evaluated on Accumulation of excess iron, inhibition of topoisomerase 2ß, and oxidative cardiac damage. Terminalia muelleri attenuates excess iron accumulation, topoisomerase 2ß inhibition, and oxidative cardiac damage in rats with doxorubicin-induced cardiotoxicity.
Synapse has enriched 10 related papers. Consider them for comparative context: